Impact Biomedical, Inc. · AMEX:IBO
Impact Biomedical — Investor Presentation (January 2025)
19 slides from Impact Biomedical's investor presentation, January 2025
Slide 1: New Solutions in Human Health and Wellness
January 2025 NEW SOLUTIONS IN HUMAN HEALTH AND WELLNESS www.ImpactBiomedInc.com
Slide 2: Safe Harbor
This presentation contains certain forward-looking statements within the meaning of the federal securities laws. These statements may be made a part of this presentation or by reference to other documents we file with the SEC. Some of the forward-looking statements can be identified by the use of fo
Slide 3: Executive Summary
EXECUTIVE SUMMARY Impact Biomedical Inc. (NYSE American: IBO) Discovers, Confirms, and Patents unique science and technologies with an emphasis on natural and plant-based technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners t
Slide 4: Core Technologies
LINEBACKER LineBacker is a platform electrophilically enhanced polyphenols to induce potency, efficacy, and bioavailability, without compromising safety standards. EQUIVIR Equivir technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols that have demonstrated antiv
Slide 5: Linebacker "LB" Core Insights
LINEBACKER “LB” Core Insights Modified Myricetin, LINEBACKER Polyphenols are a large family of naturally occurring phenols. They are abundant in plants and structurally a plant derived flavonoid that What is a diverse. Polyphenols include phenolic acids, exhibits strong antioxidant, Polyphenol? flav
Slide 6: Linebacker's Efficient Development Pathway
LINEBACKER’S Efficient Development Pathway COMMERCIAL & MARKET POTENTIAL Lung cancer is leading cause of cancer deaths Partnership with ProPhase Labs (NASDAQ: PRPH) worldwide: Lung cancer (who.int) Global Development Colon cancer is the second leading cause & Commercialization Partner: Oncology Neur
Slide 7: Equivir/G (Flavonoids) At a Glance
EQUIVIR /G (FLAVONOIDS) At a Glance Two Discreet Products With Novel blend of generally recognized as safe (GRAS) polyphenols. EQUIVIR Polyphenol blends: APPLICATIONS / INDICATION Myricetin Hesperitin Piperine Gallic Acid OTC Medication vegetables, nuts, berries, citrus fruits black pepper grapes, s
Slide 8: Equivir/G Positive Preliminary Results Highlight Promise
EQUIVIR /G (FLAVONOIDS) Positive Preliminary Results Highlight Promise Global Development & Commercialization Partner: Health Supplement Offering – OTC Upper Respiratory Disorders ➢ Initial 150 patient group, approximately 46 incidences of upper COMMERCIAL & respiratory viral infections MARKET POTEN
Slide 9: 3F Functional Fragrances Overview
3F FUNCTIONAL FRAGRANCES OVERVIEW • Suite of “functional fragrances” 3F Terpenes are highly aromatic containing specialized botanical ingredients compounds that determine the (e.g., terpenes) with potential application as an smell of many plants and herbs, antiviral or as an insect repellent (e.g. m
Slide 10: 3F Functional Fragrances Development & Commercial Opportunity
3F FUNCTIONAL FRAGRANCES Development & Commercial Opportunity COMMERCIAL & MARKET POTENTIAL • Vector-borne diseases account for more than 17% of all infectious diseases, causing more than 700k deaths annually. Chemia Corp. Global Asset available • Malaria is a parasitic infection transmitted by Anop
Slide 11: Laetose High-Level Snapshot
Laetose High-Level Snapshot TM A form of sugar found in your body, in some foods Laetose TM and as a supplement. Your body needs inositol for • Unique combination of multiple sugars independently with inositol, the development and growth of cells. Research which demonstrates the ability to suggests
Slide 12: Laetose Immediate Development & Partnership Availability
LaetoseTM Immediate Development & Partnership Availability COMMERCIAL & MARKET POTENTIAL U.S. Inflammatory Disease Treatment Market: Estimated $35B (source: Precedence Research 2022) U.S. Refined Sugar Production Market: Development Partners Development Status Estimated $12B • Manufacturing establis
Slide 13: Upcoming Milestones (FDA/EMA Regulatory Pathway)
Upcoming Milestones (FDA/EMA Regulatory Pathway) 2024 2025 2026 Timeline Oct. Nov. Dec. Jan. Feb. Mar. Q2 Q3 Q4 Q1 Preclinical study anticipated for results in Q1 2025 Targeting partnership / out-licensing agreement by end of Q1 2025 Linebacker Laetose Biopharmaceuticals for Pharmaceuticals for anti
Slide 14: Upcoming Milestones (Direct-to-consumer)
Upcoming Milestones (Direct-to-consumer) 2024 2025 2026 Timeline Oct. Nov. Dec. Jan. Feb. Mar. Q2 Q3 Q4 Q1 Human study results anticipated in Q1 2025 Targeting partnership / out-licensing agreement by end of Q1 2025 Targeting partnership / out-licensing agreement by end of Q1 2025 3F (Functional Fra
Slide 15: Intellectual Property
INTELLECTUAL PROPERTY PATENTS ISSUED AND PATENTS PENDING ACROSS ALL PLATFORMS 39 Issued U.S. Patents 50+ Patents Pending
Slide 16: Executive Officers
EXECUTIVE OFFICERS Frank D. Heuszel is the CEO of Impact Biomedical, leveraging deep experience in executive management, finance, and strategic development. Previously holding senior roles in commercial banking, he became Frank D. Heuszel CEO of parent company DSS, Inc. in 2019. Chief Executive Offi
Slide 17: Board of Directors
BOARD OF DIRECTORS Frank D. Heuszel Jason Grady Dr. Elise Brownell Melissa Sims, Esq. Castel Hibbert David Keene Chris Zimmerman CEO & Chairman Board Board Board Board Board Board of Board Member Member Member Member Member Member Frank D. Heuszel has Jason T. Grady serves as Dr. Elise Brownell, Ph.
Slide 18: Why Invest in Impact Biomedical
Unique Early-Stage Healthcare Company Proven Business Model with Leveraging both Regulatory AND an Experienced Management Team Direct to Consumer (OTC) Pathways De-risked opportunity with FOUR Novel Intellectual Property Portfolio Different Platform Technologies spanning across 8 issued patents and
Slide 19: For More Information Contact
www.ImpactBiomedInc.com FOR MORE INFORMATION CONTACT: FRANK D. HEUSZEL, President & CEO fheuszel@impactbiomedinc.com / +1 (281) 415-6576
Impact Biomedical — Investor Presentation (January 2025) on 6ix